Generation of a parvovirus B19 vaccine candidate

Vaccine

Volumn 31, Issue 37, 2013, Pages 3872-3878

  Chandramouli, Sumana ^a   Medina Selby, Angelica ^b   Coit, Doris ^b   Schaefer, Mary ^a   Spencer, Terika ^a   Brito, Luis A ^a   Zhang, Pu ^a   Otten, Gillis ^a   Mandl, Christian W ^a   Mason, Peter W ^a   Dormitzer, Philip R ^a   Settembre, Ethan C ^a  

^a Novartis Vaccines Cambridge   (United States)

^b Novartis Diagnostics   (United States)

Author keywords

Parvovirus B19; Vaccine; Virus like particle; VLP

Indexed keywords

ALUMINUM POTASSIUM SULFATE; IMMUNOGLOBULIN G; MIFAMURTIDE; NEUTRALIZING ANTIBODY; PARVOVIRUS B19 VIRUS LIKE PARTICLE VACCINE; PHOSPHOLIPASE A2; PROTEIN VP1; PROTEIN VP2; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE CHROMATOGRAPHY; ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DENSITOMETRY; DNA FLANKING REGION; DOSE RESPONSE; DOWN REGULATION; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; HUMAN PARVOVIRUS B19; IMMUNIZATION; INSECT CELL; LIGHT SCATTERING; MIXED INFECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SUCROSE GRADIENT; VIRION; VIRUS LIKE AGENT; VIRUS PURIFICATION; WESTERN BLOTTING; WILD TYPE; YEAST CELL;

PARVOVIRUS B19; VACCINE; VIRUS-LIKE PARTICLE; VLP;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CAPSID PROTEINS; FEMALE; MICE; MICE, INBRED BALB C; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PHOSPHOLIPASES A2; POLYSORBATES; SACCHAROMYCES CEREVISIAE; SQUALENE; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84881557289     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.062     Document Type: Article

References (31)

1. Young N.S., Brown K.E. Parvovirus B19. N Engl J Med 2004, 350:586-597.
2. Anderson M.J., Lewis E., Kidd I.M., Hall S.M., Cohen B.J. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (Lond) 1984, 93:85-93.
3. Smith-Whitley K., Zhao H., Hodinka R.L., Kwiatkowski J., Cecil R., Cecil T., et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004, 103:422-427.
4. Brown K.E., Green S.W., Antunez de Mayolo J., Bellanti J.A., Smith S.D., Smith T.J., et al. Congenital anaemia after transplacental B19 parvovirus infection. Lancet 1994, 343:895-896.
5. Kurtzman G.J., Cohen B.J., Field A.M., Oseas R., Blaese R.M., Young N.S. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989, 84:1114-1123.
6. Wildig J., Michon P., Siba P., Mellombo M., Ura A., Mueller I., et al. Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis 2006, 194:146-153.
7. Wildig J., Cossart Y., Peshu N., Gicheru N., Tuju J., Williams T.N., et al. Parvovirus B19 infection and severe anaemia in Kenyan children: a retrospective case control study. BMC Infect Dis 2010, 10:88.
8. Enders M., Weidner A., Zoellner I., Searle K., Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004, 24:513-518.
9. Valeur-Jensen A.K., Pedersen C.B., Westergaard T., Jensen I.P., Lebech M., Andersen P.K., et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA 1999, 281:1099-1105.
10. Nagel H.T.C., de Haan T.R., Vandenbussche F.P.H.A., Oepkes D., Walther F.J. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 2007, 109:42-47.
11. Dennis E.A., Cao J., Hsu Y-H., Magrioti V., Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011, 111:6130-6185.
12. Saikawa T., Anderson S., Momoeda M., Kajigaya S., Young N.S. Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol 1993, 67:3004-3009.
13. Tsao E.I., Mason M.R., Cacciuttolo M.A., Bowen S.H., Folena-Wasserman G. Production of parvovirus B19 vaccine in insect cells co-infected with double baculoviruses. Biotechnol Bioeng 1996, 49:130-138.
14. Ballou W.R., Reed J.L., Noble W., Young N.S., Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003, 187:675-678.
15. Bernstein D.I., Sahly El H.M., Keitel W.A., Wolff M., Simone G., Segawa C., et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011, 1-7.
16. Bansal G.P., Hatfield J.A., Dunn F.E., Kramer A.A., Brady F., Riggin C.H., et al. Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 1993, 167:1034-1044.
17. Bostic J.R., Brown K.E., Young N.S., Koenig S. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay. J Infect Dis 1999, 179:619-626.
18. Lowin T., Raab U., Schroeder J., Franssila R., Modrow S. Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors. J Vet Med B Infect Dis Vet Public Health 2005, 52:348-352.
19. Zádori Z., Szelei J., Lacoste M.C., Li Y., Gariépy S., Raymond P., et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001, 1:291-302.
20. Cotmore S.F., Tattersall P. Characterization and molecular cloning of a human parvovirus genome. Science 1984, 226:1161-1165.
21. Lin S., Arcangel P., Medina-Selby A., Coit D., Ng P., Nguyen S., et al. Design of novel conformational and genotype-specific antigens for improving sensitivity of immunoassays for hepatitis C virus-specific antibodies. J Clin Microbiol 2005, 43:3917-3924.
22. Flessel M.C., Brake A.J., Thorner J. The MF alpha 1 gene of Saccharomyces cerevisiae: genetic mapping and mutational analysis of promoter elements. Genetics 1989, 121:223-236.
23. Vajdy M., Selby M., Medina-Selby A., Coit D., Hall J., Tandeske L., et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 2006, 87:2253-2262.
24. Wong S., Brown K.E. Development of an improved method of detection of infectious parvovirus B19. J Clin Virol 2006, 35:407-413.
25. Filippone C., Franssila R., Kumar A., Saikko L., Kovanen P.E., Söderlund-Venermo M., et al. Erythroid progenitor cells expanded from peripheral blood without mobilization or preselection: molecular characteristics and functional competence. PLoS ONE 2010, 5:e9496.
26. Wong S., Zhi N., Filippone C., Keyvanfar K., Kajigaya S., Brown K.E., et al. Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol 2008, 82:2470-2476.
27. Emini E.A., Ellis R.W., Miller W.J., McAleer W.J., Scolnick E.M., Gerety R.J. Production and immunological analysis of recombinant hepatitis B vaccine. J Infect 1986, 13:3-9. Suppl A.
28. Mach H., Volkin D.B., Troutman R.D., Wang B., Luo Z., Jansen K.U., et al. Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 2006, 95:2195-2206.
29. Rosenfeld S.J., Yoshimoto K., Kajigaya S., Anderson S., Young N.S., Field A., et al. Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest 1992, 89:2023-2029.
30. Kaufmann B., Chipman P.R., Kostyuchenko V.A., Modrow S., Rossmann M.G. Visualization of the externalized VP2 N termini of infectious human parvovirus B19. J Virol 2008, 82:7306-7312.
31. Kurtzman G., Frickhofen N., Kimball J., Jenkins D.W., Nienhuis A.W., Young N.S. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989, 321:519-523.